9a4f9e4a-dc97-4f8d-9075-537b62fb98d3
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.500
- COAGULATION+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- GLYCOLYSIS+0.400
- HYPOXIA+0.400
- MYOGENESIS+0.400
- ANGIOGENESIS+0.300
- APICAL_JUNCTION+0.300
- KRAS_SIGNALING_DN+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
Top 10 suppressed
- ANDROGEN_RESPONSE-0.400
- UV_RESPONSE_DN-0.400
- INTERFERON_ALPHA_RESPONSE-0.300
- MITOTIC_SPINDLE-0.300
- PROTEIN_SECRETION-0.300
- G2M_CHECKPOINT-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
- MYC_TARGETS_V1-0.200
- ALLOGRAFT_REJECTION-0.100
- E2F_TARGETS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG486 | — | — | 0.834 |
| 2 | 09f758e5-6be1-4f29-ac92-869d92f8fbcf | — | — | 0.829 |
| 3 | b9189c77-004e-461a-9c15-b504b12a3030 | — | — | 0.824 |
| 4 | 40b92a76-f324-4cdd-8209-517d021acd47 | — | — | 0.813 |
| 5 | MNG413 | — | — | 0.809 |
| 6 | MBCProject_1151_T1_RNA | — | B | 0.793 |
| 7 | R170 | — | — | 0.792 |
| 8 | 80bea63b-bc3a-4999-8c11-a35c92183cd7 | — | — | 0.786 |
| 9 | MNG589 | — | — | 0.785 |
| 10 | d496ef4f-4716-4e6e-94e3-fce93b26d4ee | — | — | 0.785 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.500 | Inavolisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.400 | Inavolisib | — uncovered |
| HYPOXIA | 0.400 | Idelalisib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.200 | Idelalisib | — uncovered |